Clinical Trials Logo

Clinical Trial Summary

The objective of this open-label, single arm, monocentric, phase I/II clinical study is to assess safety and efficacy of ARSA gene transfer in the brain of children affected with early onset forms of Metachromatic Leukodystrophy (MLD). For this purpose, an adeno-associated virus serotype rh.10 (AAVrh.10) vector will be used to transfer the ARSA cDNA coding for Arylsulfatase A (ARSA) enzyme into the brain of children. Five patients with early onset form of MLD, age ranging from 6 months to 4 years, will be included in this protocol and will be followed during 24 months. Patients will be selected at presymptomatic or early stage of their disease, following clinical, neuropsychological and brain imaging criteria. Twelve simultaneous injections of the investigational medicinal product will be performed in the white matter of both brain hemispheres, through 6 image-guided tracks, with 2 deposits per track. A low dose (1x10EXP12 vg total) will be administered to the first 2 patients, while the last 3 will receive a higher dose (4x10EXP12 vg total). Safety and efficiency will be evaluated based on clinical, neuropsychological, radiological, electrophysiological and biological parameters.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01801709
Study type Interventional
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date June 2014
Completion date May 2029

See also
  Status Clinical Trial Phase
Completed NCT00383448 - HSCT for High Risk Inherited Inborn Errors Phase 2
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT01303146 - Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Active, not recruiting NCT04628364 - The Natural History of Metachromatic Leukodystrophy Study (HOME Study)
Enrolling by invitation NCT05368038 - ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Completed NCT00683189 - Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy N/A
Recruiting NCT02171104 - MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Phase 2
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Active, not recruiting NCT03392987 - A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD) Phase 2
Recruiting NCT02559830 - Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Phase 1/Phase 2
Active, not recruiting NCT00639132 - The Natural History of Metachromatic Leukodystrophy
Completed NCT00004378 - Stem Cell Transplantation (SCT) for Genetic Diseases N/A
Completed NCT00176904 - Stem Cell Transplant for Inborn Errors of Metabolism Phase 2/Phase 3
Active, not recruiting NCT04283227 - OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD) Phase 3
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Recruiting NCT04925349 - Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Active, not recruiting NCT00005900 - Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation N/A
Active, not recruiting NCT01560182 - Gene Therapy for Metachromatic Leukodystrophy (MLD) Phase 1/Phase 2
Completed NCT01586455 - Human Placental-Derived Stem Cell Transplantation Phase 1